Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isotretinoin in Treatment of COVID-19
NCT04353180Phase 3Unknown
- Sponsor
- Kafrelsheikh University
- Start
- Aug 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of isotretinoin in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Kafrelsheikh University. Primary endpoint: Lung Injury Score at 14 days. Status: unknown.
02
Drugs
isotretinoin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04353180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04353180.